Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study of APG-115 Alone or in Combination With Azacitidine in Patients With Relapse/Refractory AML, CMML or MDS

NCT04358393 is registered in ClinicalTrials.gov with Ascentage Pharma Group Inc. as lead sponsor.

NCT NCT04358393
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04358393 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study of APG-115 Alone or in Combination With Azacitidine in Patients With Relapse/Refractory AML, CMML or MDS
Lead sponsor
Ascentage Pharma Group Inc.
Phase
Phase 1/2
Overall status
Unknown status
Start date
December 4, 2020
Completion date
December 30, 2025
Enrollment
69 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, aml, chronic myelomonocytic leukemia, cmml, high-risk myelodysplastic syndrome, mds, myelodysplastic syndromes